Cameron Diaz on Menopause: What She's Said and How a Regular Patient Gets the Same Care

What Cameron Diaz Has Actually Said About Menopause

Cameron Diaz has not made a detailed public statement specifying a personal menopause treatment regimen. She has spoken openly and positively about women's aging, menopause as a biological reality, and the need for women to understand their bodies at every life stage. Her 2016 book, "The Longevity Book: The Science of Aging, the Biology of Strength, and the Privilege of Time," co-authored with Sandra Bark, addressed the science of female aging directly and without apology.

In interviews around that book's release, Diaz framed menopause not as a loss of femininity but as a biological transition that women deserve honest information about. She has spoken on podcasts and in print about how women are frequently left underprepared for perimenopause and the years that follow.

What "The Longevity Book" Actually Covers

The book dedicates substantial space to female hormonal biology, including how estrogen levels shift across a woman's reproductive life, the physiology of aging ovaries, and why symptoms vary so widely between individuals. Diaz and Bark drew on scientific literature to present menopause not as an ending but as a distinct biological phase with its own demands on sleep, bone density, cardiovascular health, and cognitive function.

That framing is consistent with current clinical thinking. The Menopause Society (formerly NAMS) states that menopause is a natural biological process, and that treating its symptoms is a legitimate medical priority, not a cosmetic one.

What Is Inference vs. Confirmed

To be precise about the limits of public reporting: Diaz has not confirmed publicly that she takes hormone therapy or any specific menopause medication. Any reports suggesting she takes a named drug or follows a specific protocol should be treated as speculation unless she has said so directly in a verifiable interview or social post. This article will not state she takes a treatment she has not confirmed. What she has confirmed is a commitment to women understanding their own physiology across every life stage.

What Perimenopause and Menopause Actually Involve

Menopause is defined clinically as 12 consecutive months without a menstrual period, in the absence of other causes. The average age of natural menopause in the United States is 51.4 years, according to data published in the American Journal of Obstetrics and Gynecology.

Perimenopause, the transition phase leading up to that point, typically begins in a woman's mid-to-late 40s but can start earlier. It lasts an average of 4 to 8 years, though some women experience it for a decade or more.

Symptoms Across Life Stages

Symptoms are not uniform. They shift depending on where you are in the transition.

Reproductive years (late 30s to early 40s, early perimenopause): Cycles may become irregular. PMS may worsen. Sleep disruption and mood changes often appear before hot flashes do. Many women at this stage are still trying to conceive or using contraception, which adds a layer of complexity to any hormonal management.

Mid-to-late perimenopause (typically mid-40s to early 50s): Vasomotor symptoms, including hot flashes and night sweats, peak in frequency and intensity during this window. Up to 80% of women experience vasomotor symptoms during the menopausal transition, according to the Study of Women's Health Across the Nation (SWAN). Vaginal dryness, disrupted sleep, and cognitive fog become more common.

Post-menopause: Hot flashes may continue for years. Genitourinary syndrome of menopause (GSM) affects roughly 27% to 84% of post-menopausal women, causing vaginal dryness, dyspareunia (pain with sex), and urinary urgency. Bone density loss accelerates in the first 3 to 5 years after the final period.

Female-Specific Physiology That Matters

Estrogen is not only a reproductive hormone. It regulates cardiovascular function, bone remodeling, lipid metabolism, mood signaling, and skin collagen synthesis. When ovarian estrogen production declines, these systems all feel the effect. This is why menopause is not simply a gynecological event. It is a whole-body transition that affects a woman's metabolic and cardiovascular risk profile for the rest of her life.

The Treatment Options a Regular Patient Can Access

The following framework describes the actual treatment ladder available to a woman in the U.S. Today, moving from most evidence-supported to adjunctive options. This is not unique to celebrities. Every option listed below is accessible through a primary care provider, an OB-GYN, a NAMS-certified menopause practitioner, or a telehealth platform.

Menopausal Hormone Therapy (MHT / HRT)

Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and GSM in women who are eligible for it. The Menopause Society's 2022 position statement on hormone therapy states that for healthy women under 60 or within 10 years of menopause onset, the benefits of MHT generally outweigh the risks for the treatment of bothersome menopausal symptoms.

Estrogen options:

• Oral estradiol (0.5 mg to 2 mg daily, dose-adjusted to symptom control)
• Transdermal estradiol patch (doses ranging from 0.025 mg/day to 0.1 mg/day)
• Transdermal estradiol gel or spray
• Vaginal estradiol (ring, cream, or tablet, for local GSM treatment only)

Progestogen requirement: Any woman with an intact uterus needs a progestogen alongside systemic estrogen to protect the uterine lining from unopposed estrogen-driven hyperplasia. Options include oral micronized progesterone (Prometrium), medroxyprogesterone acetate, levonorgestrel IUD, or norethindrone acetate.

A 2019 analysis in the BMJ found that certain progestogen formulations, particularly synthetic progestins, carry a higher associated breast cancer risk than micronized progesterone. This is a meaningful clinical distinction, and worth discussing with your prescriber.

Who is typically eligible: Women under 60, within 10 years of menopause onset, with no personal history of hormone-receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, or prior venous thromboembolism. ACOG Practice Bulletin 141 outlines the contraindications and risk stratification process in detail.

Non-Hormonal Prescription Options

For women who cannot or choose not to use hormone therapy, several evidence-based options exist.

Fezolinetant (Veozah): A neurokinin B receptor antagonist approved by the FDA in May 2023 specifically for moderate to severe vasomotor symptoms in menopause. It acts on the hypothalamic thermoregulation pathway without hormonal activity. The SKYLIGHT 1 and SKYLIGHT 2 trials found fezolinetant 45 mg daily reduced hot flash frequency by approximately 60% at week 12 compared to placebo.

Paroxetine 7.5 mg (Brisdelle): The only FDA-approved SSRI for vasomotor symptoms. Modestly effective for hot flash frequency. Note that paroxetine interacts with tamoxifen, making it a poor choice for women on that breast cancer therapy.

Venlafaxine, escitalopram, gabapentin: Frequently used off-label with reasonable evidence for symptom reduction. None are approved for this indication, but they appear in clinical practice guidelines as second-line options.

Vaginal (Local) Estrogen for GSM

Vaginal estrogen, applied locally, carries minimal systemic absorption and is generally considered safe even for many women with a history of breast cancer, pending oncologist review. ACOG and The Menopause Society both support the use of low-dose vaginal estrogen for GSM symptoms. Ospemifene (Osphena), an oral SERM, is an alternative for women who prefer not to use vaginal preparations.

Lifestyle Approaches With Evidence

These are adjuncts, not replacements for pharmacological management in women with moderate-to-severe symptoms.

• Weight management: Body fat is a source of estrogen conversion via aromatase. However, higher BMI is associated with more severe hot flashes, not fewer, because impaired heat dissipation worsens symptom intensity.
• Cognitive behavioral therapy (CBT): A Cochrane review found CBT reduced the problem rating of hot flashes significantly, though it did not reduce objective frequency as much as MHT.
• Pelvic floor physical therapy: Directly addresses urinary urgency and dyspareunia associated with GSM. Underused and highly effective.
• Resistance training: Protects bone mineral density during the post-menopausal accelerated loss window. Consistent evidence across multiple observational and intervention studies.

Pregnancy, Lactation, and Contraception: What Changes Around This Life Stage

This section addresses something that gets missed constantly in mainstream menopause content. Perimenopause does not mean infertility. Contraception is still required if pregnancy is not desired.

Can You Get Pregnant in Perimenopause?

Yes. Ovulation is irregular in perimenopause but not absent. ACOG advises that women should continue contraception until 12 consecutive months of amenorrhea have been confirmed. Unintended pregnancy rates in women aged 40 to 44 remain meaningful, and pregnancies in this age group carry higher risks for chromosomal abnormalities, gestational diabetes, and preeclampsia.

Hormone Therapy Is Not Contraception

MHT doses of estrogen are lower than those in combined oral contraceptives and do not reliably suppress ovulation. A woman in perimenopause who starts MHT for symptoms still needs a separate contraceptive method if she is sexually active and does not want to conceive.

Good options during perimenopause:

• Levonorgestrel IUD (also provides the progestogen component of MHT)
• Progestin-only pill
• Barrier methods
• Low-dose combined oral contraceptive pill (if no contraindications, and she is under 50 and a non-smoker)

Hormone Therapy During Pregnancy

Systemic MHT is contraindicated in pregnancy. If a woman on MHT discovers she is pregnant, she should discontinue immediately and contact her obstetric provider. Data on inadvertent first-trimester estrogen exposure are limited but have not shown a clear teratogenic signal at low doses. The priority is confirming the pregnancy, stopping MHT, and arranging appropriate prenatal care.

Hormone Therapy and Breastfeeding

Systemic estrogen therapy is generally avoided during lactation because estrogen can suppress milk production. Vaginal estrogen at low doses has minimal systemic absorption and may be considered on a case-by-case basis postpartum for women experiencing significant vaginal atrophy, but this scenario is uncommon and should be discussed with both an OB-GYN and a lactation consultant.

PCOS, Thyroid Disease, and Other Female Conditions That Interact With Menopause

Women do not arrive at menopause with a blank hormonal history. Several conditions common in women of reproductive age alter the menopausal experience and treatment decisions.

PCOS and Menopause

Women with polycystic ovary syndrome often have higher androgen levels and different estrogen exposure patterns throughout their reproductive years. Research published in Human Reproduction suggests women with PCOS may experience menopause somewhat later than the general population, possibly due to a larger antral follicle count at baseline. However, metabolic risks, including insulin resistance and cardiovascular risk, continue post-menopause and may be amplified. These women need careful metabolic monitoring alongside any menopause treatment.

Thyroid Disease

Hypothyroidism and hyperthyroidism both produce symptoms that overlap significantly with perimenopause: fatigue, mood changes, irregular periods, and sleep disruption. Thyroid function testing is a standard part of any thorough perimenopause workup. The American Thyroid Association estimates thyroid disorders affect approximately 20 million Americans, with women 5 to 8 times more likely to be affected than men. Missing a thyroid diagnosis in a perimenopausal woman is a common clinical error.

Premature Ovarian Insufficiency (POI)

Some women experience menopause before age 40. This is called premature ovarian insufficiency, affecting approximately 1% of women under 40. POI carries heightened risks for cardiovascular disease and osteoporosis compared with natural menopause at the typical age. Hormone therapy in POI is both a symptom treatment and a risk-reduction strategy, and should generally continue at minimum until the average age of natural menopause.

How a Regular Patient Actually Gets This Care

The care Cameron Diaz advocates for, including honest medical attention, access to evidence-based symptom management, and clinicians who take menopause seriously, is not reserved for people with celebrity connections or unlimited budgets. Here is a realistic access pathway.

Step 1: Find a Menopause-Informed Provider

Not every primary care provider or OB-GYN has up-to-date menopause training. The Menopause Society maintains a free "Find a Provider" directory at menopause.org that lists certified practitioners by zip code. NAMS certification requires demonstrated knowledge of current guidelines.

Telehealth menopause platforms have substantially expanded access in the past five years. A NAMS-certified or menopause-focused provider can evaluate you, order labs, and prescribe appropriately in most U.S. States without an in-person visit.

Step 2: Know What Labs to Expect

A standard perimenopause or menopause workup typically includes:

• FSH (follicle-stimulating hormone): elevated FSH, typically above 30 IU/L in the context of symptoms and irregular periods, supports but does not definitively diagnose menopause
• Estradiol
• TSH (thyroid-stimulating hormone, to exclude thyroid cause of symptoms)
• A fasting lipid panel and fasting glucose (metabolic baseline)
• Bone density (DEXA scan) at or around menopause onset, especially with any risk factors

As WomanRx clinical reviewer Elena Vasquez, MD, puts it: "The biggest mistake I see is women waiting years before anyone takes their symptoms seriously. A 47-year-old with night sweats, irregular periods, and mood shifts is almost certainly in perimenopause, and she deserves a real treatment conversation the first time she walks in, not reassurance that everything is fine."

Step 3: Prepare for Your Appointment

Bring a symptom diary covering at least 4 weeks. Note:

• Cycle length, flow, and any spotting
• Frequency and severity of hot flashes or night sweats (rate 1 to 10)
• Sleep quality and disruptions
• Mood, anxiety, or cognitive changes
• Any vaginal symptoms or changes in sexual function
• Current medications and supplements

This data shortens the diagnostic process and helps your provider calibrate treatment options correctly.

Step 4: Understand Your Options Before You Walk In

Women who arrive at appointments knowing the difference between systemic and local estrogen, between MHT and non-hormonal options, and between perimenopause and post-menopause get better care. This is not because their doctor responds to pressure. It is because shared decision-making produces better-matched treatment choices. Read the Menopause Society's patient resources before your visit.

Step 5: Telehealth as a Real Option

For women without a local menopause specialist, telehealth platforms staffed by NAMS-certified providers can prescribe FDA-approved menopause treatments, including estradiol patches, gels, and oral progesterone, and ship them to most states. Typical first visit involves a video consultation, an intake questionnaire, and a lab review. Follow-up visits are used to adjust dosing.

Insurance coverage for telehealth menopause care has expanded since 2020. Generics of estradiol patches and oral micronized progesterone are widely available for under $30 per month at major pharmacies with a GoodRx coupon.

Who This Treatment Path Is Right For (and Who Should Be More Cautious)

Well-Matched Candidates for MHT

• Women aged 45 to 60, within 10 years of menopause onset, with moderate to severe vasomotor symptoms
• Women with GSM affecting quality of life or sexual function
• Women with early menopause or POI (hormone therapy is strongly recommended in this group)
• Women with reduced bone density who are not candidates for or prefer not to start bisphosphonates

Women Who Need Individualized Risk Assessment First

• Women with a personal history of hormone-receptor-positive breast cancer (non-hormonal options are typically first line; discuss with oncologist)
• Women with a history of venous thromboembolism (transdermal estrogen carries lower thrombotic risk than oral; risk assessment required)
• Women with active liver disease
• Women with unexplained vaginal bleeding (must be evaluated before starting MHT)
• Women with cardiovascular disease or a prior stroke (higher risk; individualize carefully)

The Evidence Gap: What We Still Do Not Know

Women were significantly underrepresented in early hormone therapy research, and the Women's Health Initiative (WHI) trial, which generated widespread fear about HRT starting in 2002, enrolled women with an average age of 63, well outside the window where benefits are greatest. Subsequent reanalysis and the WHI substudy of women aged 50 to 59 showed a more favorable benefit-risk ratio in younger, recently menopausal women. Long-term safety data on newer non-hormonal agents like fezolinetant in women with comorbidities remain limited. This is an honest gap in the evidence, and your provider should acknowledge it.